Juvenile idiopathic arthritis

14 trials 10 recruiting MedDRA PT
14 Registered trials
10 Recruiting
11 Unique sponsors
15 Unique IMPs
10 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
L Oncology (ATC L) 8
Mechanism of action (INN-stem analysis)
JAK inhibitor 5 substances
Monoclonal antibody (human) 3 substances
Receptor fusion protein 2 substances
EGFR inhibitor 1 substance
Monoclonal antibody 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Monoclonal antibody (humanized) 1 substance
Antimetabolite 1 substance
Phase III: 7 Phase II/III: 1 Phase II: 1 Phase IV: 3 Phase I (Other): 2

Filter these 14 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 14 trials

Phase III

7 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    TOCILIZUMAB; UPADACITINIB
    2022-501599-25-00 8 countries 2024 n=33
    Recruiting
  • Alfasigma S.p.A. Commercial
    FILGOTINIB
    2024-511593-70-00 10 countries 2026 n=57
    Recruiting
  • Alfasigma S.p.A. Commercial
    FILGOTINIB
    2025-523239-21-00 2 countries 2026 n=18
    Recruiting
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    DEUCRAVACITINIB
    2024-517262-41-00 6 countries 2025 n=29
    Recruiting
  • UCB Biopharma Commercial
    BIMEKIZUMAB
    2023-508845-41-00 4 countries 2025 n=28
    Recruiting
  • Duke Clinical Research Institute Academic
    ABATACEPT; ADALIMUMAB; ETANERCEPT; TOCILIZUMAB; TOFACITINIB
    2025-520923-25-00 3 countries n=45
    Pending
  • Giannina Gaslini Institute For Scientific Hospitalization And Care Academic
    ETANERCEPT; METHOTREXATE
    2023-505051-43-00 1 country 2024 n=260
    Recruiting

Phase II/III

1 trial
  • Pfizer Inc. Commercial
    TOFACITINIB CITRATE
    2023-509651-14-00 3 countries 2013 n=8
    Ended

Phase II

1 trial
  • Sanofi-Aventis Recherche & Developpement Commercial
    SARILUMAB
    2024-512701-11-00 11 countries 2018 n=37
    Recruiting

Phase IV

3 trials
  • Novartis Pharma AG Commercial
    IMP not specified
    2023-504417-67-00 7 countries 2020 n=323
    Recruiting
  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico Academic
    ADALIMUMAB; ETANERCEPT
    2024-515557-22-00 1 country 2022 n=290
    Ended
  • IRCCS Istituto Giannina Gaslini Academic
    ABATACEPT; ADALIMUMAB; BARICITINIB; ETANERCEPT; GOLIMUMAB; METHOTREXATE; SECUKINUMAB; TOCILIZUMAB; TOFACITINIB
    2024-514732-24-00 7 countries 2025 n=328
    Recruiting

Phase I (Other)

2 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    UPADACITINIB
    2023-505060-11-00 5 countries 2019 n=104
    Recruiting
  • Alfasigma S.p.A. Commercial
    FILGOTINIB
    2023-505844-21-00 4 countries 2024 n=50
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Alfasigma S.p.A. Commercial 3 Phase I (Other), Phase III 2
AbbVie Deutschland GmbH & Co. KG Commercial 2 Phase I (Other), Phase III 2
Pfizer Inc. Commercial 1 Phase II/III 0
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase II 1
Bristol-Myers Squibb Services Unlimited Company Commercial 1 Phase III 1
UCB Biopharma Commercial 1 Phase III 1
Novartis Pharma AG Commercial 1 Phase IV 1
Duke Clinical Research Institute Academic 1 Phase III 0
Giannina Gaslini Institute For Scientific Hospitalization And Care Academic 1 Phase III 1
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico Academic 1 Phase IV 0
IRCCS Istituto Giannina Gaslini Academic 1 Phase IV 1
New trials by year
2019
1
2020
1
2022
1
2024
3
2025
3
2026
2
← All indication landscapes